Porter R S
Drug Intell Clin Pharm. 1984 Jan;18(1):42-51. doi: 10.1177/106002808401800106.
This article reviews the efficacy of NSAIDs and their pharmacokinetic and pharmacodynamic properties. The assumption that classic pharmacokinetic dose/plasma concentration response relationships can be applied to NSAIDs has tenuous support in the biomedical literature. Comparative efficacy studies, using ASA and indomethacin as the standards for comparison, ignore the fact that the major outcome variables are subjective responses among patients, not among drugs. Comparing inhibition of platelet malonyldialdehyde, synovial drug concentrations, urinary prostaglandin metabolites, and plasma free and total concentration with the clinical outcome provides no guidelines to serve as predictors of response. The individual agents, indomethacin, salicylates, sulindac, piroxicam, and naproxen, illustrate the complexities of NSAID pharmacotherapy. Recent proliferation of newer NSAIDs will not add significantly to the efficacy of these agents in the treatment of pain and inflammatory disease states. However, knowledge of pharmacokinetic population parameters for the individual NSAIDs will increase the likelihood of therapeutic success and diminish the possibilities for adverse reactions.
本文综述了非甾体抗炎药(NSAIDs)的疗效及其药代动力学和药效学特性。经典药代动力学剂量/血浆浓度反应关系可应用于NSAIDs这一假设在生物医学文献中的支持力度微弱。以阿司匹林(ASA)和吲哚美辛作为比较标准的疗效对比研究,忽略了主要结局变量是患者个体的主观反应而非药物之间的反应这一事实。将血小板丙二醛抑制、滑膜药物浓度、尿前列腺素代谢产物以及血浆游离和总浓度与临床结局进行比较,无法提供作为反应预测指标的指导原则。吲哚美辛、水杨酸盐、舒林酸、吡罗昔康和萘普生等个体药物,体现了NSAIDs药物治疗的复杂性。近期新型NSAIDs的大量涌现,并不会显著增加这些药物在治疗疼痛和炎症性疾病方面的疗效。然而,了解个体NSAIDs的药代动力学群体参数,将增加治疗成功的可能性并减少不良反应的发生几率。